Full Press Release Details
| Dr. Reddy's Laboratories Ltd. | |
| 8-2-337, Road No. 3, Banjara Hills, | |
| Hyderabad - 500 034, Telangana, | |
| India. | |
| CIN: L85195TG1984PLC004507 | |
| Tel : +91 40 4900 2900 | |
| Fax : +91 40 4900 2999 | |
| Email : mail@drreddys.com | |
| www.drreddys.com |
| Corporate Relationship Department | National Stock Exchange of India Ltd. | ||
| BSE Limited | "Exchange Plaza" | ||
| Dalal Street, Fort | Bandra-Kurla Complex, Bandra (East), | ||
| Mumbai - 400 001 | Mumbai - 400 051 | ||
| Fax Nos.: | 022-22723121 / 22723719 / | Fax Nos.: | 022-26598120/ 26598237/ |
| 22722037 / 22722039 | 26598238 | ||
| Scrip Code: 500124 | Scrip Code: DRREDDY-EQ |
Please find enclosed a Press Release on
"Dr. Reddy's Laboratories announces the launch of Tobramycin Inhalation Solution, USP in the U.S. Market"
This is for your information.
| Vikas Sabharwal | |
| Assistant Company Secretary |
CC:- New York Stock Exchange Inc.(Stock Code :RDY)
| CONTACT | ||
| DR. REDDY'S LABORATORIES LTD. | Investor relationS | Media relationS |
| 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500034. Telangana, India. | AMIT AGARWAL amita@drreddys.com (Ph: +91-40-49002135) | MITALI SARKAR mitali.sarkar@drreddys.com (Ph: +91-40- 49002121) |
Laboratories announces the launch of Tobramycin Inhalation
Solution, USP in the U.S. Market
Hyderabad, India and Princeton, NJ, USA. June 25, 2019 -
Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as
"Dr. Reddy's") today announced the launch of Tobramycin Inhalation Solution, USP a therapeutic equivalent generic
version of TOBI (tobramycin) Inhalation Solution, approved by the U.S. Food and Drug Administration (USFDA).
The TOBI (tobramycin) Inhalation Solution brand
and generic had U.S. sales of approximately $97 million MAT for the most recent twelve months ending in April 2019 according to
Dr. Reddy's Tobramycin Inhalation Solution, USP is available
in a 300 mg/5 mL, single-dose Ampule.
Tobi is a trademark of Mylan.
*IQVIA Retail and Non-Retail MAT April 2019.
About Dr. Reddy's: Dr. Reddy's Laboratories
Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) is an integrated pharmaceutical company, committed to providing affordable and innovative
medicines for healthier lives. Through its three businesses - Pharmaceutical Services & Active Ingredients, Global Generics
and Proprietary Products - Dr. Reddy's offers a portfolio of products and services including APIs, custom pharmaceutical
services, generics, biosimilars and differentiated formulations. Our major therapeutic areas of focus are gastrointestinal, cardiovascular,
diabetology, oncology, pain management and dermatology. Dr. Reddy's operates in markets across the globe. Our major markets
include - USA, India, Russia & CIS countries, and Europe. For more information, log on to: www.drreddys.com
Disclaimer: This press release may include statements
of future expectations and other forward-looking statements that are based on the management's current views and assumptions
and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially
from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the
words "may", "will", "should", "expects", "plans", "intends", "anticipates",
"believes", "estimates", "predicts", "potential", or "continue" and similar expressions
identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements
due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults , currency
exchange rates , interest rates , persistency levels and frequency / severity of insured loss events (ii) mortality and morbidity
levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and
in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganization , including related integration
The company assumes no obligation to update any information